HAEMONETICS CORP Quarterly Revenue from Contract with Customer, Excluding Assessed Tax in USD from Q2 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Haemonetics Corp quarterly/annual Revenue from Contract with Customer, Excluding Assessed Tax history and growth rate from Q2 2017 to Q3 2024.
  • Haemonetics Corp Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending September 28, 2024 was $346M, a 8.59% increase year-over-year.
  • Haemonetics Corp Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending September 28, 2024 was $1.36B, a 9.84% increase year-over-year.
  • Haemonetics Corp annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $1.31B, a 12% increase from 2022.
  • Haemonetics Corp annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $1.17B, a 17.7% increase from 2021.
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $1.36B $346M +$27.3M +8.59% Jun 30, 2024 Sep 28, 2024 10-Q 2024-11-07
Q2 2024 $1.33B $336M +$24.8M +7.98% Mar 31, 2024 Jun 29, 2024 10-Q 2024-08-08
Q1 2024 $1.31B $343M +$38.9M +12.8% Dec 31, 2023 Mar 30, 2024 10-K 2024-05-20
Q4 2023 $1.27B $336M +$30.9M +10.1% Oct 1, 2023 Dec 30, 2023 10-Q 2024-02-08
Q3 2023 $1.24B $318M +$20.7M +6.96% Jul 2, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $1.22B $311M +$49.9M +19.1% Apr 2, 2023 Jul 1, 2023 10-Q 2024-08-08
Q1 2023 $1.17B $304M +$39.4M +14.9% Jan 1, 2023 Apr 1, 2023 10-K 2024-05-20
Q4 2022 $1.13B $305M +$45.5M +17.5% Oct 2, 2022 Dec 31, 2022 10-Q 2024-02-08
Q3 2022 $1.08B $297M +$57.6M +24% Jul 3, 2022 Oct 1, 2022 10-Q 2023-11-02
Q2 2022 $1.03B $261M +$32.9M +14.4% Apr 3, 2022 Jul 2, 2022 10-Q 2023-08-08
Q1 2022 $993M $265M Jan 2, 2022 Apr 2, 2022 10-K 2024-05-20
Q4 2021 $260M +$19.4M +8.07% Oct 3, 2021 Jan 1, 2022 10-Q 2023-02-07
Q3 2021 $240M +$30.4M +14.5% Jul 4, 2021 Oct 2, 2021 10-Q 2022-11-08
Q2 2021 $229M +$33M +16.8% Apr 4, 2021 Jul 3, 2021 10-Q 2022-08-10
Q4 2020 $240M -$18.6M -7.18% Sep 27, 2020 Dec 26, 2020 10-Q 2022-02-08
Q3 2020 $209M -$43.1M -17.1% Jun 28, 2020 Sep 26, 2020 10-Q 2021-11-09
Q2 2020 $196M -$42.9M -18% Mar 29, 2020 Jun 27, 2020 10-Q 2021-08-11
Q4 2019 $259M +$11.6M +4.7% Sep 29, 2019 Dec 28, 2019 10-Q 2021-02-02
Q3 2019 $253M +$11M +4.55% Jun 30, 2019 Sep 28, 2019 10-Q 2020-11-04
Q2 2019 $238M +$9.1M +3.97% Mar 31, 2019 Jun 29, 2019 10-Q 2020-08-04
Q4 2018 $247M +$13.3M +5.69% Sep 30, 2018 Dec 29, 2018 10-Q 2020-02-04
Q3 2018 $242M +$16.2M +7.19% Jul 1, 2018 Sep 29, 2018 10-Q 2019-11-01
Q2 2018 $229M +$18.4M +8.72% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q4 2017 $234M Oct 1, 2017 Dec 30, 2017 10-Q 2019-02-05
Q3 2017 $225M Jul 2, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 $211M Apr 2, 2017 Jul 1, 2017 10-Q 2018-08-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.